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RNA interference (RNAi), a mediator of gene silencing, has swiftly become one of the most exciting
and applicable biological discoveries. There has been rapid progress in identifying RNAi pathway
components and elucidating the mechanisms of microRNA (miRNA) biogenesis and gene suppres-
sion. As a result, RNAi technologies have been successfully employed in a variety of systems as
biological tools, and studies are underway to test the therapeutic utility of RNAi. In the span of several
years, significant advances in the delivery of inhibitory RNAs in the nervous system have been made.
We have glimpses into how endogenous miRNAs interface with neuronal development and function;
in addition, RNAi has shown therapeutic efficacy in several mouse models of human neurological
conditions. In this review, we summarize the current state-of-the-art of RNAi and its utility to neuro-
scientists.RNA interference (RNAi) refers to the mechanism of gene
silencing imparted by small noncoding RNAs with varying
levels of sequence complementarity to an mRNA target.
RNAi has evolved from a confusing experimental result
in plant and worm studies to a now well-characterized
process of gene expression control in multiple species.
The recent awarding of the Nobel Prize in Medicine &
Physiology to researchers C. Mello and A. Fire for the dis-
covery of RNAi (Fire et al., 1998) solidifies its standing
among one of the major discoveries in cell biology.
RNAi for regulation of gene expression occurs naturally
in cells via microRNAs (miRNAs) and likely other noncod-
ing RNAs. miRNAs are transcribed by RNA polymerase II
as primary miRNAs (Cai et al., 2004; Lee et al., 2004) or,
for a subset of miRNAs, polymerase III (Borchert et al.,
2006) (Figure 1). In mammalian systems and worms,
pri-miRNAs are processed by Drosha-DGCR8, the micro-
processor complex, to an 60–70 nucleotide pre-miRNA
(Gregory et al., 2004; Lee et al., 2003; Yeom et al., 2006;
Zeng et al., 2005). In flies, the microprocessor compo-
nents are termed Drosha and Pasha (Denli et al., 2004).
Pre-miRNAs are subsequently exported to the cytoplasm
(Lund et al., 2004; Yi et al., 2003) and processed further by
Dicer-1-TRBP in mammals (Haase et al., 2005; Provost
et al., 2002), Dicer-1-Loquacious in Drosophila (Forste-
mann et al., 2005; Saito et al., 2005), or Dicer-RDE-4 in
C. elegans (Grishok et al., 2001; Tabara et al., 2002), yield-
ing21 bp small duplex RNAs. In mammalian cells, TRBP
recruits Ago2 (Chendrimada et al., 2005), a component of
the miRNA-induced silencing complex (miRISC), after
which final miRNA maturation and gene silencing occurs
(Chu and Rana, 2006; Gregory et al., 2005).miRNAs in Neuroscience
Investigators in neuroscience are now capitalizing on the
discovery of RNAi in a variety of ways. Primary among
them is profiling miRNAs in development and disease to
better understand their expression patterns, identifying
miRNA targets to reveal their biological role, and as a
tool to inhibit gene expression in cells and animals. miRNA
profiling is being assessed by various approaches. Direct
cloning and miRNA microarrays have been used to iden-
tify tissue-specific miRNAs but typically do not resolve
to the cellular level. In situ hybridization and the use of
RNAi sensors (reporters containing artificial miRNA bind-
ing sites in the 30UTR) are more suitable strategies for
identifying cell-type-specific miRNAs (Bentwich et al.,
2005; Johnston and Hobert, 2003; Kloosterman et al.,
2006; Liang et al., 2005; Mansfield et al., 2004; Mourelatos
et al., 2002; Nelson et al., 2004, 2006). With the latter
approach, silencing of the reporter occurs in cells that
express the corresponding miRNAs (Brennecke et al.,
2003; Johnston and Hobert, 2003). The RNAi sensor
method has been applied to neuronally expressed
miRNAs in invertebrates (Johnston and Hobert, 2003),
and proof-of-principle studies in mouse peripheral tissues
have been reported (Mansfield et al., 2004).
miRNA expression is often temporally and spatially re-
stricted at the cellular and subcellular level, imparting roles
in brain morphogenesis (Aboobaker et al., 2005; Giraldez
et al., 2005; Mansfield et al., 2004; Nelson et al., 2006; Vo
et al., 2005) and neuronal cell fate (Krichevsky et al., 2003;
Conaco et al., 2006; Krichevsky et al., 2006; Smirnova
et al., 2005; Wu and Xie, 2006). For example, Conaco
and colleagues recently showed that some miRNAs areNeuron 53, March 15, 2007 ª2007 Elsevier Inc. 781
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in nonneuronal cells. When REST-mediated repression
of the miRNAs was relieved, a neuronal phenotype was
promoted in part through miRNA-mediated inhibition
of nonneuronal protein expression (Conaco et al., 2006).
In worms, asymmetric expression of miRNAs lys-6 and
miR-273 in sensory neurons establishes chemosensory
laterality (Chang et al., 2004b; Johnston and Hobert,
2003). Recent evidence suggests that asymmetric miRNA
expression may also occur in vertebrates. Wheeler and
colleagues cloned CNS-specific miRNAs and showed by
in situ hybridization that miR-500 was expressed strongly
in the right versus the left developing limb bud (Wheeler
et al., 2006). At the cellular level, polarity of miRNA expres-
sion is exemplified bymiR-134a (Schratt et al., 2006). miR-
134a is localized to the synapse of hippocampal neurons
and contributes to dendritic spine development by inhibit-
ing expression of Limk1, a dendritically translated protein.
Target identification is of paramount importance to un-
derstanding the biological function of miRNAs. Bioinfor-
matic approaches have been developed by a number of
investigators (Krek et al., 2005; Kruger and Rehmsmeier,
2006; Lewis et al., 2003; Xie et al., 2005), but as yet, the
number of putative targets for miRNA-mediated silencing
far outnumber those that have been experimentally con-
firmed. The predictive power ofmany programs is crippled
in part because only a small region of the miRNA, known
as the seed region (Lewis et al., 2005), needs to retain
Figure 1. A Cartoon Depicting the Endogenous Pathway for
Processing of miRNAs, and RNAi Tools that Can Co-Opt This
Pathway at Various Points for Silencing of Intended Targets782 Neuron 53, March 15, 2007 ª2007 Elsevier Inc.base-pairing with the mRNA target to mediate transla-
tional repression (Didiano and Hobert, 2006; Sethupathy
et al., 2006). Wet-lab techniques for the identification of
miRNA targets have also been developed. One method
uses differential centrifugation to identify mRNAs that shift
to the heavy polyribosome fractions following inhibition of
a particular miRNA (Nakamoto et al., 2005). Recently,
Vinther and colleagues cleverly employed a stable isotope
labeling approach to the problem. Identification of miRNA
targets was accomplished by comparing LC-MS/MS data
of tryptic peptides acquired from cells grown in media
containing stable heavy isotope-labeled amino acids
plus the query miRNA to mock-transfected cells grown
in naturally occurring amino acids (Vinther et al., 2006).
RNAi as a Tool
The utility of RNAi as a biological tool is limited primarily by
our ability to introduce inhibitory sequences into desired
cells or tissues. Inhibitory RNAs can be designed to mimic
primary miRNA stem-loops, processed pre-miRNAs
(short-hairpin RNAs or shRNAs), or mature miRNAs with
perfect complementarity to their targets (small interfering
RNAs or siRNAs) (Figure 1). siRNAs and shRNAs were
among the first to be used in cell-free, cell culture, and
animal systems. siRNAs are double-stranded effecter
molecules, generally 19–22 bp in length, that are loaded
directly into RISC following transfection into cells (Elbashir
et al., 2001). shRNAs are stem-loop structures expressed
from vector systems, generally with strong, constitutive
Pol III promoters (Paul et al., 2002; Sui et al., 2002), al-
though Pol II systems can be used (Xia et al., 2002). Since
shRNAs are expressed in the nucleus, they are designed
to mimic Drosha-processed pre-miRNAs for efficient nu-
clear export. More recently, investigators have embedded
siRNA sequences into pri-miRNA stem-loop structures
that enter the RNAi pathway upstream of Drosha (Zeng
et al., 2002). This approach more naturally resembles en-
dogenous RNAi, thus improving subsequent processing
steps (Boden et al., 2004). Polycistronic transcripts
containing multiple stem-loops have been developed for
targeting different sequences within a particular mRNA
or targeting multiple unique mRNAs (Chung et al., 2006).
Engineered miRNAs serving as siRNA shuttles have also
been inserted into introns or the 30 UTR of reporters (Cai
et al., 2004; Lin and Ying, 2006).
Designing Inhibitory RNAs
Effective RNAi requires careful consideration of the se-
quences used for silencing target mRNAs. siRNAs may
be ineffective if the inappropriate (sense) strand is prefer-
entially loaded over the intended guide (antisense) strand.
However, this problem can usually be avoided by design-
ing siRNA duplexes with lower thermodynamic stability at
the 50 end of the antisense strand (Khvorova et al., 2003;
Schwarz et al., 2003). This not only promotes loading of
the appropriate guide strand, but reduces the likelihood
of off-targeting mediated by the sense strand (discussed
below). Even with appropriate strand loading, an siRNA
Neuron
Primermay still be nonfunctional if the sequence within the
targeted transcript is inaccessible due to secondary and
tertiary structures or associated proteins (Brown et al.,
2005; Overhoff et al., 2005). Thus, several candidate
siRNAs must be screened initially to identify effective
gene silencers. Various web-based programs may assist
candidate selection by identifying target sites that satisfy
strand-biasing guidelines and additional criteria that pro-
mote effective silencing and reduce off-targeting (Naito
et al., 2004).
Candidate siRNAs may be screened by various means
to identify sequences that mediate the level of silencing
that best suits the researchers’ needs. Cell-free assays
have been successfully employed to measure siRNA-
mediated cleavage of radio-labeled target mRNAs (Elba-
shir et al., 2001). This direct approach allows confirmation
that the mRNA is cleaved within the target site. Alterna-
tively, gene silencing can be assessed by real-time quan-
titative PCR (preferred) or Western blot analysis (depen-
dent upon protein half-life) following transfection of RNAi
into cell cultures. With this method, the target mRNA
may be expressed endogenously or from cotransfected
plasmids (Paul et al., 2002; Sui et al., 2002; Xia et al.,
2002, 2004). The latter approach is generally done in cells
that are highly transfectable (e.g., HEK293). The approach
is efficient since most cells receive both target and inhib-
itory RNA (or plasmid expressing such) due to the nature
of transfection, and both are expressed at roughly the
same time. This provides a good method for screening
inhibitory RNAs and certainly makes sense for targets ex-
pressed only in neurons. Conversely, silencing of endoge-
nous mRNAs may be limited by transfection efficiency,
particularly when the treated population is analyzed as
a whole. For large-scale screens, the use of reverse trans-
fection (overlaying cells onto siRNA-spotted slides,
Mousses et al., 2003) coupled with luciferase or fluores-
cent-tagged targets may expedite candidate siRNA
identification.
The Side Effects of Silencing
The specificity of RNAi must be considered for its applica-
tion as a biological or therapeutic tool. While many studies
support the potency and specificity of siRNA approaches,
the issue of specificity across tissues and cell types re-
mains unresolved, as microarray studies have revealed
both specificity and the lack of it (Chi et al., 2003; Jackson
et al., 2003; Semizarov et al., 2003).
Off-targeting may occur if siRNAs bind to and regulate
unintended mRNA targets. There are algorithms available
that predict potential transcripts that may be unintention-
ally silenced due to partial complementarity (Naito et al.,
2004; Yamada and Morishita, 2005). Off-targeting is
primarily mediated through the seed region, which may
direct translational repression of unintended targets,
through pairingwith the 30 untranslated region of anmRNA
(Birmingham et al., 2006). Testing several functional
sequences against a target and, if possible, performingrescue studies will help address whether off-target effectsare confounding experimental results. Furthermore, for
siRNAs, addition of 20-O-methyl modifications to the
seed regions greatly limits off-target gene silencing
(Fedorov et al., 2006; Jackson et al., 2006).
More than 20 years ago it was shown that long dsRNAs,
when introduced into mammalian cells, would activate in-
nate immune responses mediated by PKR and interferon
(IFN), resulting in global gene silencing (Manche et al.,
1992; Minks et al., 1979). It is now clear that some siRNAs
and shRNAs can induce IFN responses in a dose- and se-
quence-dependent manner in vitro (Bridge et al., 2003;
Fish and Kruithof, 2004; Pebernard and Iggo, 2004; Sledz
et al., 2003). In slice culture neurons, some shRNAs acti-
vated IFN via PKR resulting in phenotypic changes (i.e., al-
tered electrophysiological readouts and loss of synapses
and dendritic spines) (Alvarez et al., 2006). These findings
reiterate the importance of validating RNAi experiments
by testing several sequences. In addition to responses
mediated by PKR, siRNAs may also activate IFN via toll-
like receptors (TLR) TLR7 and TLR8, which recognize
siRNAs within the endosome (Hornung et al., 2005; Mar-
ques and Williams, 2005). Recently, immunostimulatory
sequence motifs have been identified that should be
avoided when selecting RNAi target sequences (Hornung
et al., 2005; Judge et al., 2005). Furthermore, modifying
the siRNAs at the termini of the sense strand significantly
reduces the immunostimulatory activity (Hornung et al.,
2005; Morrissey et al., 2005).
Engineered siRNAs, shRNAs, and miRNAs utilize en-
dogenous RNAi machinery and can therefore at high
doses cause toxicity independent of sequence. shRNAs
are designed to resemble pre-miRNAs and are typically
expressed at high levels. Abundant shRNAs likely out-
compete endogenous pre-miRNAs for nuclear export ma-
chinery, which may result in cellular toxicity (Grimm et al.,
2006). Changing the inhibitory RNA from a shRNA to one
that is pri-miRNA-based can greatly reduce nuclear accu-
mulation and subsequent toxicity due to saturation of
endogenous machinery (R.L.B. and B.L.D., unpublished
data). This effect is mostly attributable to dosing; engi-
neered pri-miRNAs may be less well transcribed or less
stable than optimized shRNAs. To date there is no evi-
dence that siRNAs are capable of saturating RNAi ma-
chinery but, as stated above, can be problematic at doses
greater than 10 nM. Thus, sequences that reduce ex-
pression of the intended target at high picomolar to low
nanomolar doses (in vitro) are ideal.
RNAi for Neuroscientists: Applications
Researchers have induced RNAi experimentally through
the exogenous addition of siRNAs or through the use of
vectors expressing shRNAs or engineered pri-miRNAs to
a variety of biological systems (Figure 2). InC. elegans, ex-
ogenously triggered RNAi directed at target genes is often
accomplished by generating transgenic lines expressing
shRNA transgenes from inducible and/or tissue-specific
promoters (Wang and Barr, 2005). Interestingly, in wild-
type worms, neurons are resistant to RNAi administeredNeuron 53, March 15, 2007 ª2007 Elsevier Inc. 783
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PrimerFigure 2. Survey of Currently Used
Methods for Achieving RNAi in Worms,
Flies, Cell Culture, and Mammalsvia feeding of bacteria expressing dsRNA (Kamath et al.,
2003). However, mutant lines with neurons sensitive to
this delivery method have been generated and used for
RNAi screens to identify genes important to neuronal syn-
apse development and function (Sieburth et al., 2005).
RNAi screens in neurons have also been successful in
Drosophila. Several genes, including transcription factors
required for proper development of the embryonic ner-
vous system, were identified following injection of dsRNA
libraries into fly embryos (Ivanov et al., 2004; Parrish et al.,
2006).
In general, cultured neurons are not easily transfected
with plasmid DNAs using most commercial reagents. Be-
cause siRNAs need merely enter cytoplasmic RISC for
silencing activity, the cell membrane poses the main
transfection barrier, making them more amenable than
plasmids to standard transfection protocols. Researchers
often use siRNAs, either purchased commercially or gen-
erated at the bench, that can be complexed with a variety
of transfection reagents, some developed specifically for
siRNAs. Recent work indicates that ‘‘dicer-ready’’ siRNAs
of 26–27 nucleotides are more potent than the shorter
sequences in tissue culture cells (Kim et al., 2005).
In addition to whole cells, transfection into spatially re-
stricted areas of neurons has also been accomplished.
Hengst and coworkers transfected siRNAs targeting
RhoA directly into the distal axons of dorsal root ganglia
(Hengst et al., 2006). Silencing was seen in the transfected
axon, but not more proximal axons or cell bodies. This ap-
proachmay allow spatial resolution ofmRNA transcripts in
neurons at the subcellular level.
Transfection into organotypic slice cultures has also
been done (Boda et al., 2004; Shima et al., 2004; Gaudil-
lie`re et al., 2004). To assess the role of flamingo, a member
of the cadherin superfamily, in the growth and mainte-
nance of dendrites, plasmids expressing inhibitory RNAs
were conjugated with gold particles and biolistically trans-
fected into neurons (Shima et al., 2004). In other studies,
Boda and coworkers biolistically transfected siRNAs into
slice cultures to test the role of the mental retardation pro-784 Neuron 53, March 15, 2007 ª2007 Elsevier Inc.tein Pak3 in hippocampal synaptic plasticity, (Boda et al.,
2004).
The longevity of RNAi induced by transfection of siRNAs
or dicer substrates may be insufficient for some in vitro
studies (often fewer than 14 days). In these instances,
viral-mediated expression of either shRNAs (Gonzalez-
Alegre et al., 2005) or engineered pri-miRNAs (Stegmeier
et al., 2005) can be used. Lentivirus-based vector systems
are often employed for cell culture work because they are
simple and inexpensive to make. Moreover, because they
integrate into the genome, they can be used to generate
stable cell lines. Lentiviruses based on feline immunodefi-
ciency virus (FIV) or human immunodeficiency virus (HIV)
have been optimized to elicit stable and regulated RNAi
(Harper et al., 2006; Wiznerowicz and Trono, 2003).
Naked and complexed siRNAs have been successfully
delivered to the CNS and PNS of rodents (Dorn et al.,
2004; Salahpour et al., 2006; Tan et al., 2005; Thakker
et al., 2004). siRNAs can be introduced acutely or through
the use of implanted pumps. Complexing siRNAs with
lipids or other transfection reagents allows for lower dos-
ing, but toxicity of the complexing agent is always a con-
sideration. Researchers have directly injected or used
pumps to deliver siRNAs to reduce expression of P2X3
in nociceptive sensory neurons, NR2B and delta opioid
receptors in sensory neurons, and dopamine transporter
in the striatum and substantia nigra. In addition, intraven-
tricular injection of siRNA into neonatal mice decreased
target gene expression (Wang et al., 2005). Using these
approaches, siRNA-mediated gene silencing remains
transient and typically requires continual or repeated
delivery for long-term studies.
Long-term RNAi may be achieved with lentiviruses,
adenoviruses, and adeno-associated viruses that have
been engineered to deliver inhibitory RNAs to the nervous
system. The first demonstrations of in vivo delivery to the
brain were accomplished with adenoviruses expressing
shRNAs targeting transgenic eGFP (Xia et al., 2002) or
plasmids expressing shRNAs against agouti-related pep-
tide (Makimura et al., 2002). These studies were followed
Neuron
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associated viruses (Harper et al., 2005; Hommel et al.,
2003; Miller et al., 2005; Ralph et al., 2005; Rodriguez-
Lebron et al., 2005; Xia et al., 2004) and lentiviruses (Raoul
et al., 2005; Singer et al., 2005) to brain, spinal cord, and
muscle. To date, all vector-expressed RNAi used in silenc-
ing CNS and PNS targets has been in the form of shRNAs
driven by either Pol II or Pol III expression systems.
Though considerable efficacy was observed, much of
the early work was done using shRNAs harboring se-
quences that were not optimized for guide-strand loading
into RISC since rules for strand biasing were unknown at
the time. With strand-biasing knowledge now in hand,
more appropriate RNAi-expressing vectors can be devel-
oped for future application to neuroscience in mammals.
Further improvements may be achieved by utilizing engi-
neered pri-miRNAs that give researchers opportunities
to coexpress RNAi and reporters via tissue-specific or
regulated promoters, thus enhancing the versatility of
RNAi in vivo (Zeng et al., 2002).
Finally, neurobiologists have also used engineered in-
hibitory RNAs as novel therapeutic strategies for treating
neurological disorders. Several groups have successfully
employed RNAi to treat mouse models of various human
neurological conditions, including Huntington’s disease,
Alzheimer’s, Spinocerebellar Ataxia Type I, Amyotrophic
Lateral Sclerosis, and pain, among others (Dorn et al.,
2004; Harper et al., 2005; Makimura et al., 2002; Miller
et al., 2005; Ralph et al., 2005; Raoul et al., 2005; Salah-
pour et al., 2006; Singer et al., 2005; Tan et al., 2005;
Thakker et al., 2004; Xia et al., 2002, 2004).
The Next Step: Regulated Expression
The application of RNAi has already been enhanced with
the development of controlled expression vectors. Regu-
lated RNAi expression has been achieved via ecdysone-
or tetracycline-inducible systems (Gupta et al., 2004;
Matsukura et al., 2003). Tet-based systems have been
successfully incorporated into viral vectors allowing sta-
ble, inducible silencing in vitro and in vivo (Hosono et al.,
2004; Shin et al., 2006; Wiznerowicz and Trono, 2003).
However, transgenic mice expressing tet-inducible RNAi
have yet to be generated. To date, inducible RNAi trans-
genics have relied primarily upon Cre-LoxP systems
(Chang et al., 2004a). Inducible RNAi strategies provide
a method to generate models where sufficient target
gene expression is essential for organism development
or viability. However, RNAi approaches will yield knock-
downs as opposed to true knockouts produced with the
traditional Cre-LoxP methods. Nonetheless, the ability to
reduce gene expression with precise timing allows re-
searchers to assess gene function during various develop-
mental stages. Inducible systems can also be exploited to
express natural miRNAs to elucidate their respective roles
in developmental processes. Moreover, controlled ex-
pression can be combined with tissue-specific strategies
to allow both temporal and spatial restriction of RNAi.
These approaches continue to be fine-tuned for tightregulation and may also benefit therapeutic applications
of RNAi.
Conclusion
We have learned much about the biochemistry underlying
RNAi since the recent discovery of RNAi by Fire andMello.
However, we are only in the initial stages of understanding
miRNA’s role in neural development, synaptic function,
animal behavior, and disease. The techniques for harness-
ing RNAi as a biological tool and therapeutic approach will
continue to evolve as we discover new ways in which to
co-opt the elegant RNAi pathway for use in neuroscience
and medicine.
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